Ocugen (OCGN) Exchange Rate Effect (2018 - 2026)
Ocugen's (OCGN) quarterly Exchange Rate Effect came in at $102000.0 in Q1 2026, up 1375.0% YoY from $6915.3 in Q1 2025, and up 3300.0% on a QoQ basis from $3000.0 in Q4 2025.
Powered by 
Analysis
Ocugen (OCGN) Exchange Rate Effect (2018 - 2026) Analysis & Trends
Ocugen (OCGN) has 7 years of Exchange Rate Effect data on file, last reported at $102000.0 in Q1 2026.
- Quarterly Exchange Rate Effect rose 1375.0% year-over-year to $102000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $123000.0 (up 720.0% YoY) and the FY2025 annual result came in at $13000.0, down 53.57% from the prior year.
- Exchange Rate Effect advanced to $102000.0 in Q1 2026, from $3000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $102000.0 in Q1 2026 to a low of -$28000.0 in Q2 2025.
- A 5-year average of $10187.5 and a median of $3000.0 in 2024 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2025 — Exchange Rate Effect slumped 1033.33% — and 2026, when it surged 1375.0%.
- Tracing OCGN's Exchange Rate Effect over 5 years: stood at -$5000.0 in 2022, then sank by 40.0% to -$7000.0 in 2023, then soared by 457.14% to $25000.0 in 2024, then tumbled by 88.0% to $3000.0 in 2025, then soared by 3300.0% to $102000.0 in 2026.
- The last three Exchange Rate Effect figures came in at $102000.0 (Q1 2026), $3000.0 (Q4 2025), and $46000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | 49,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 49,000.00 |
| Mar 31, 2026 | 102,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Dec 31, 2023 | -7,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | -2,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Dec 31, 2022 | -5,000.00 |
| Sep 30, 2022 | 20,000.00 |
| Jun 30, 2022 | 10,000.00 |
| Sep 30, 2019 | 99.00 |
| Jun 30, 2019 | 183.00 |
| Mar 31, 2019 | -282.00 |